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Skin cancer is the most common
form of cancer in the United
States. In 2004, over 50,000
people were diagnosed with skin
cancer and about 8,000 people
died due to skin cancer. Risk
factors for developing skin cancer include blue or green eyes,
blonde or red hair, family history, sun exposure, and a history
of sunburns during childhood.
Additional risk factors include
people with light natural skin
color and skin that burns, freckles, or reddens easily.1
Exposure to ultraviolet (UV)
rays ages the skin, leads to sunburned skin, and causes precancerous and cancerous lesions.
Additionally, immunosuppressive effects may be observed,
including suppression of contact
hypersensitivity, delayed-type
hypersensitivity, and changes in
cell function. Exposure to UVA
radiation is associated with skin
aging and changes in pigmentation, while UVB causes sunburns, which alters the genetic
makeup possibly leading to skin
cancer.2,3
Sunscreens contain filters that
block UV rays. The amount of

protection from UVB radiation is
measured by the sun protective
factor (SPF) of a sunscreen. For
example, if a person usually experiences skin redness after 10
minutes of sun exposure, a SPF 15
sunscreen would provide protection against sunburn for 150 minutes. In addition, a person who
usually experiences redness after
5 minutes of sun exposure would
need a SPF 30 product to be protected from the sun for 150 minutes. These estimations are based
on appropriate application of sunscreen and reapplication after
sweating or swimming.2-4
Sunscreens are categorized by the
type of UV filter within the formulation (Table 1). Metal oxides,
such as zinc oxide, titanium dioxide, and iron oxide, are inorganic
filters that protect against UVA
and UVB radiation by deflecting
light energy.3-5
Another category of sunscreens,
organic sunscreens, convert UV
radiation into heat radiation to
protect the skin. Organic sunscreens are characterized by the
type of UV filter and coverage
provided. However, for maximum UV protection, a sunscreen
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Table 1: Types of UV Filters3,5
Category
UVA

Examples

Features

Issues

Mexoryl™

Photo-stable, water resistant,
found in cosmetic products

More expensive

Aminobenzoate

PABA

Durable

Photoallergic reaction, yellow discoloration, possible carcinogenic
byproducts

Cinnamate

Cinoxate, Octinoxate

Water soluble, low skin irritation
potential

Cross reaction with cocoa leaves

Salicylate

Octyl salicylate, homosalate,
triethanolamine salicylate

High durability, photo-stable,
favorable safety profile

Skin reactions rare

Benzophenone

Oxybenzone, sulisobenzone,
dioxybenzone

Well-tolerated

Most allergenic, poor durability

Ensulizole

PBSA

Water soluble

Skin reactions rare

Metal oxide

Zinc oxide, titanium dioxide,
iron oxide

High durability, long-lasting

Less cosmetic appeal

Octocrylene

Avobenzone (Parsol® 1789,
Helioplex™)

Well-tolerated

Lacks durability, more expensive

Ecampsule
UVB

UVA and UVB

Table 2. Products Containing Filters Protecting Against UVA and/or UVB Radition6
Product
Inorganic filters

UV Filter

Cost*

Features

Titanium dioxide

$11.59
3.5 oz

Waterproof, less sensitizing

Athelios SX® Daily
Moisturizing Sunscreen

Avobenzone, Ecamsule, Octocrylene

$28.49
3.4 oz

Long-lasting hydration, broad protection

Aveeno® Sunblock

Avobenzone, Homosalate, Octisalate, Octocrylene, Oxybenzone

$9.99
4 oz

Oil-free, contains vitamins A, C, and E

Banana Boat® Sunblock

Avobenzone, Homosalate, Oxybenzone, Octisalate, Octocrylene

$8.19
8 oz

Sweatproof, waterproof, non-greasy

Blue Lizard Australian®

Octinoxate, Octocrylene, Oxybenzone, Zinc Oxide

$12.49
5 oz

Bottle indicates exposure to UV light,
long-lasting

Bull Frog Quik Gel®

Octinoxate, Octisalate, Octocrylene,
Oxybenzone

$9.49
5 oz

Dries quickly, non-greasy

Coppertone® Sport

Homosalate, Octinoxate, Octisalate,
Oxybenzone

$10.49
8 oz

Sweatproof, waterproof

Hawaiian Tropic®

Homosalate, Octocrylene, Octinoxate, Oxybenzone, Octisalate

$10.71
8 oz

Sweatproof, waterproof, non-greasy

Neutrogena® Ultra Sheer

Avobenzone, Homosalate, Octisalate, Octocrylene, Oxybenzone

$9.99
3 oz

Sweatproof, waterproof, non-greasy

PreSun® Sensitive Sunblock
Organic filters

* Cost based on prices from www.drugstore.com on May 23, 2008.
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containing both UVA and UVB
filters should be used. Examples
of products containing both UVA
and UVB filters are listed in Table
2.3,5,6 Table 3 lists guidelines for
maximum sun protection.1,8

Table 3: Guidelines for Maximum Sun Protection1,8
▪ Stay in the shade between 10 AM and 4 PM when UV rays are the strongest
▪ Wear clothing to protect exposed skin and a hat to protect the face, ears,
head, and neck

▪ Apply sunscreen containing UVA and UVB protection with SPF 15 or higher
and reapply per product labeling

Medications may also increase the
risk of phototoxicity or sunburn
(Table 4). Commonly prescribed
medications such as furosemide,
ciprofloxacin, and sulfamethaxazole/trimethoprim can increase the
risk of sunburn. Patients taking
these medications should be cautious when outdoors.7
References available upon request

▪ Wear sunglasses that wrap around the head to block both UVA and UVB
▪ Infants less than 6 months of age should remain in shaded areas when outside
and sunscreen should be avoided. If sunscreen is necessary, it should only be
applied to areas not shaded or covered by clothing, such as the face or backs
of the hands

Table 4: Photosensitive Medications7,9,10
ACE Inhibitors
Amiodarone
Amitriptyline
Furosemide
Fluoroquinolones
Sulfonamides
Tetracyclines
Minocycline
Tacrolimus
Diltiazem

Doxycycline
Thiazides
NSAIDs
Retinoids
Sulfonylureas
Methotrexate
Chemotherapy
Isotretinoin
Verteporfin
Coal tar

Changes to Policy C78: Medication Orders
Medication Order Priorities
With the development of computerized prescriber order entry (CPOE), medication priorities needed to be set
as part of the order so that ancillaries understand when the medication order is due for administration. The following changes to the policy were approved by the Pharmacy and Therapeutics Committee and the Medical
Executive Committee (MEC):
▪ Keep STAT at “dispensed within 30 minutes”
▪ ADD “Next Schedule (NXT SCH)”
− Medication will be scheduled based on the next dose that would be due based on the frequency chosen by the prescriber.
▪

Example: medication ordered at 10 AM for Q12H dosing (9 AM/9 PM); dose would be scheduled and sent for 9 PM
administration
Add new priority of “1st NOW”
− Indicates that the first dose of the medication ordered should be dispensed now (within 2 hour time frame) from the time the
order is received. Example: medication ordered at 10 AM for Q12H dosing; however, physician would like the patient to
receive a morning dose now

Indication Requirement for Outpatient Order
In order to obtain complete financial reimbursement from insurance companies, it will be required that a diagnosis (ie, DRG code or written diagnosis) appear on all medication orders written in the clinics. This is similar
to requirements for lab and radiology orders. The change to the policy was approved by the Pharmacy and
Therapeutics Committee and MEC. The Billing and Reimbursement Task Force will provide education to the
medical staff prior to implementation.
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Did You Know…
Revisions to Pregnancy and Lactation Labeling for Prescription
Products
The Food and Drug Administration (FDA) proposed major revisions to the product labeling for
prescription drugs (including biological products) to provide better
information about the effects during pregnancy and lactation.
The proposed changes to prescription drug labeling would give
health care professionals more
comprehensive information for
making prescribing decisions and
for counseling women who are
pregnant, breast-feeding, or of
child-bearing age about using prescription medications.
There are about 6 million pregnancies in the United States every
year, and pregnant women take an
average of 3 to 5 prescription
drugs during pregnancy. Additionally, women with pre-existing
medical conditions, such as
asthma or high blood pressure,
may need to continue to use prescription drugs to treat those conditions during pregnancy.
The proposed rule outlines what
important information about the
use of medicines during pregnancy and lactation would be required to be added to product labeling for newly approved drugs.
Under the proposal, drug labeling
would explain, based on available
information, the potential benefits
and risks for the mother and the
fetus, and how these risks may
change during the course of pregnancy.

Current labeling uses a letter
category system (A, B, C, D, and
X) to describe the risks of drug
use during pregnancy. Stakeholders have said the letter category system leads to an inaccurate and overly simplified view
of these risks, and does not facilitate updating of labeling as
new information becomes available.
The proposed rule would remove
the letter categories from the
pregnancy section of prescription drug labeling. The newly
designed format for the labeling
would have the following
sections:
▪ Fetal Risk Summary: would de-

▪

▪

scribe what is known about the effects of the drug on the fetus, and if
there is a risk, whether this risk is
based on information from animals
or humans. A risk conclusion will be
based on the available data and will
provide a number of examples depending on the quality and quantity
of that data.
Clinical Considerations: would
include information about the effects
of the use of the drug if it is taken
before a woman knows she is pregnant.
Data: would describe in more detail
the available data regarding use of
the drug in humans and from animal
studies that were used to develop the
Fetal Risk Summary.

The pregnancy section would
also include information about
whether there is a pregnancy exposure registry for the drug.
Pregnancy exposure registries
collect and maintain data on the
effects of approved drugs that
are prescribed to and used by
pregnant women.

The lactation section of labeling
would use the same format as the
pregnancy section. This section
would provide information about
using the drug while breastfeeding, such as the amount of drug in
breast milk and potential effects
on the breastfed infant.
FDA expects to implement the
revised format after June 2010.
Manufacturers would then have
between 3 and 5 years to update
their labeling. Products approved
before June 2001 would not be
required to comply with the new
labeling unless an supplemental
new drug application is submitted.
However, the category A, B, C, D,
and X statement from their current
label must be removed. For more
information, visit: www.fda.gov/
cder/regulatory/
pregnancy_labeling/default.htm.

Erratum: April 2008
Issue of Pharmacy and
Therapeutics Update
The editor regrets that there was
an error in the April 2008 issue of
Pharmacy and Therapeutics Update. In the article titled “Recent
Changes to the Prescribing of
Schedule-II Controlled Substances,” a loop hole was described regarding the dating of CII
prescriptions. The 60-day limit
was part of the law in 2007; however, it has been amended to reflect the 90-day time period.
Therefore, CII prescriptions can
be written for 31 day supply and
are valid for 90 days from
date issued.
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FORMULARY UPDATE FOR APRIL/MAY 2008
The Pharmacy and Therapeutics
Committee recently approved the
actions listed below.
Addition with Restriction:
Omalizumab (Xolair®) is indicated for moderate to severe persistent asthma in patients at least
12 years of age. It is a recombinant, humanized, monoclonal antibody that selectively binds to IgE
receptors and blocks the interaction that stimulates mast cells and
basophils in allergic reactions.
The 2007 National Asthma Education and Prevention Program
(NAEPP) recommends that omalizumab may be considered as an
addition to high dose inhaled corticosteroids and long-acting beta
agonists. It is restricted to the pulmonary service for moderate to
severe persistent asthma.
Single-use, 5-mL vial: 150 mg

propriate dose of citalopram
based on the conversion chart.
Based on current usage, this
ATS should result in approximately $10,000 annual savings.
Additionally, citalopram is offered by many local pharmacies
inexpensively and is available on
Medicare Part D and South
Carolina Medicaid formularies.
The ATS protocol is posted on
the Formulary and Drug Information Resources web page.

▪ Crotaminton (Eurax®) 10% cream
[60-g tubes]

▪ Desoximetasone (Topicort®) 0.05%
▪
▪
▪
▪
▪
▪

www.formularyproductions.com/musc

▪
Line Extensions:
▪ Sodium phosphate
▪
▪

(K-Phos Neutral) [tablets]
Multiple vitamins (AquADEK®)
[soft gel capsules]
Secretin (ChiRoStim®)
[16-microgram powder for injection]

Deletions:
▪ Secretin (SecreFlo®)

▪
▪
▪
▪
▪
▪

[16-microgram powder for injection]

Added:
Iopromide (Ultravist®) is a nonionic, iodinated radiocontrast
agent. It is comparable in indications to other formulary agents
[iopamidol (Isovue®) and iodixanol (Visipaque®)]. Based on the
specific type of procedure, iopromide is comparable and/or less
expensive than similar agents on
the formulary. The iodinated radiocontrast class will undergo a
utilization
review
(inpatient/
outpatient) in 6 months.
50-, 100-, 150-mL vials: 300 mgI, 370
mgI

▪ Aprotinin (Trasylol®)
▪
▪
▪
▪
▪
▪
▪
▪
▪

Automatic Therapeutic Substitution (ATS) for Escitalopram
(Lexapro®):
Orders for escitalopram will be
automatically converted to the ap-

▪
▪

[10,000 KIU/mL injection]
Auranofin (Ridaura®)
[3-mg capsules]
Dextroamphetamine sustained release (Dexedrin®) [15-mg capsules]
Efavirenz (Sustiva®)
[50-mg capsules]
Estramustine (Emcyt®)
[140-mg capsules]
Flutamide [125-mg capsules]
Methoxsalen (8-MOP)
[10-mg capsules]
Methsuximide (Celontin®)
[300-mg capsules]
Mexiletine (Mexilet®)
[250-mg capsules]
Penicillamine (Cuprimine®)
[125- and 250-mg capsules]
Anthralin (Psoriatec®) 0.5% and 1%
cream [50-g tubes]
Betamethasone valerate 0.1% cream
[15-g tubes]

▪
▪
▪

cream [15- and 60-g tubes]
Desoximetasone (Topicort®) 5% gel
[15- and 60-g tubes]
Mafenide (Sulfamylon®) 8.5%
[57-g packet]
Sulfanilamide [15% vaginal cream]
Tretinoin (Retin-A®) 0.1% cream
[20-gram tubes]
Tretinoin (Retin-A®) 0.1% gel
[15-g tubes]
Tretinoin (Retin-A®) 0.025% gel
[15-g tubes]
Fluorescein (Ful-Glo®) ophthalmic
[1-mg strips]
Fluorescein 2% ophthalmic drops
[1-mL]
Fluorouracil (Efudex®) 5% cream
[25-g tubes]
Diazepam rectal gel [5-mg tubes]
Diazepam rectal kit (Diastat® Acudial)
[20-mg twin packs]
Fluocinonide 0.05% gel [15-g tubes]
Cyclopentolate (Cyclogyl®) 0.5%
[15-mL]
Dapiprazole (Rev-Eyes®) 0.5% ophthalmic drops [5-mL bottle]
Cromolyn (Intal®)
[800-microgram MDI]
Edrophonium chloride (Enlon® and
Enlon Plus®) [10-mg/mL injection]

Dexmedetomidine (Precedex®)
Pre-printed Order Form
A preprinted order form for dexmedetomidine orders is now available online on the Clinician Order
Form web page. The use of this
form is required per the formulary
restrictions.
Updates to the IV Push Charts
Glucagon (GlucaGen® HypoKit)
was added to the IV push charts.
The charts are located on the Formulary and Drug Information Resources web page.

